Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib Plus Atezolizumab in Advanced BRAF V600 Wild-Type Melanoma
NCT03178851Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2017
- Primary completion
- May 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of cobimetinib and atezolizumab in melanoma (3 arms), sponsored by Roche. Primary endpoints: Objective Response Rate and Disease Control Rate at Week 16. Started Jun 2017; status: completed.
02
Drugs
cobimetinibatezolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03178851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178851.